Qiagen (NYSE:QGEN) Receives $51.50 Consensus Target Price from Analysts

Qiagen (NYSE:QGEN) has earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $51.50.

Several research firms have issued reports on QGEN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 price target (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Morgan Stanley reaffirmed an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th.

Qiagen Price Performance

Shares of NYSE QGEN opened at $44.70 on Thursday. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The stock has a market cap of $10.20 billion, a P/E ratio of 114.62, a P/E/G ratio of 3.52 and a beta of 0.37. The firm’s 50-day simple moving average is $44.03 and its 200 day simple moving average is $43.92. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after acquiring an additional 500 shares in the last quarter. Toronto Dominion Bank acquired a new stake in Qiagen during the second quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Qiagen in the 3rd quarter worth approximately $53,000. Finally, Headlands Technologies LLC lifted its position in shares of Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after buying an additional 2,189 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.